Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
Ovid Therapeutics Inc. issued 10,701,710 pre-funded warrants of warrant to the Investors for purchase price of $2.009 per Pre-Funded Warrant.
- Security
- warrant
- Shares
- 10,701,710 pre-funded warrants
- Purchaser
- the Investors
- Consideration
- purchase price of $2.009 per Pre-Funded Warrant
Exact text from the filing
On March 17, 2026, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 19,154,321 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $2.01 per share and, in lieu of Common Stock, pre-funded warrants to purchase up to 10,701,710 shares of Common Stock (the “Pre-Funded Warrants” and, together with the Shares, the “Securities”) at a purchase price of $2.009 per Pre-Funded Warrant, to the Investors in a private placement (the “PIPE financing”).
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
Ovid Therapeutics Inc. issued 19,154,321 shares of common stock of common stock to the Investors for purchase price of $2.01 per share.
- Security
- common stock
- Shares
- 19,154,321 shares of common stock
- Purchaser
- the Investors
- Consideration
- purchase price of $2.01 per share
Exact text from the filing
On March 17, 2026, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 19,154,321 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $2.01 per share and, in lieu of Common Stock, pre-funded warrants to purchase up to 10,701,710 shares of Common Stock (the “Pre-Funded Warrants” and, together with the Shares, the “Securities”) at a purchase price of $2.009 per Pre-Funded Warrant, to the Investors in a private placement (the “PIPE financing”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Ovid Therapeutics Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at $60.0 million (effective 2026-03-17).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the purchasers named therein
- Value
- $60.0 million
- Effective
- 2026-03-17
Exact text from the filing
On March 17, 2026, Ovid Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 19,154,321 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $2.01 per share
View on SEC.gov